On October 17, 2022 Xspray Pharma AB reported the company has based on the authorisation granted by the annual general meeting of Xspray on 19 May 2022, and in accordance with what the Company indicated in the interim report for the second quarter of 2022, successfully carried out a fully subscribed directed share issue at a subscription price of SEK 50 per share (the "Issue") (Press release, Xspray, OCT 17, 2022, View Source [SID1234650114]). The subscription price has been negotiated at arm’s length with investors and is based on the Board’s assessment, following discussions with the Company’s financial advisor, at market conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A number of Swedish institutional investors, including Third Swedish National Pension Fund (AP3), Flerie Invest AB and Östersjöstiftelsen have subscribed for shares in the Issue. The Board has carefully considered alternative financing solutions, including the prospects to carry out a rights issue. The Board has concluded that a rights issue would take a significantly longer time to complete and entail a higher risk for a materially adverse effect on the share price, particularly in light of the market volatility and the challenging market conditions. Another important reason for deviating from the shareholders’ preferential rights is to further enhance the shareholder base with an institutional investor in the form of the Third Swedish National Pension Fund (AP3). In light of the above, the Board has made the assessment that a directed share issue with deviation from the shareholders’ preferential rights creates the best conditions to secure the Company’s continued financial stability in the current market climate and to enable market preparing activities before the upcoming launch on the American market. Overall, the Board considers that the Issue contributes to creating value for all the Company’s shareholders and is beneficial for the Company.

The Company intends to use the net proceeds from the Issue primarily to:

Market preparing activities before the upcoming launch on the American market
Continued development of the Company’s product portfolio with an initial focus on the product candidate XS003, which is the next product to be launched on the American market
To enhance the Company’s financial stability
The Issue is expected to raise proceeds for the Company of SEK 100 million, before transaction costs. The Issue will result in an increase in the number of shares in Xspray of 2,000,000, from 20,680,408 to 22,680,408, and an increase in the share capital by SEK 2,000,000 from SEK 20,680,408 to SEK 22,680,408 resulting in a dilution of approximately 8.8 percent.

Zonda Partners has acted as Bookrunner in connection with the Issue. Advokatfirman Vinge has acted as legal advisor to Xspray Pharma.

On October 17, 2022 Nexi reported that it had attracted Series A investment worth 22 billion won (Press release, NEX-I, OCT 17, 2022, View Source;mode=VIEW&num=31&category=&findType=&findWord=&sort1=&sort2=&page=2 [SID1234643439]). In addition to existing investors such as DSC Investment, Schmidt, Atinum Investment, and Hana Ventures, six institutions including Stone Bridge Ventures, TS Investment, CJ Investment, Wonik Investment Partners, Medytox Venture Investment, and GC Green Cross participated as new investors in this investment. Nexi’s cumulative investment has increased to 27 billion won, including this round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NexI plans to use this investment for research and development and preclinical testing of the company’s leading candidate substances, ‘NXI-101’ and ‘NXI-201’. Kyung-wan Yoon, CEO of Nexi, said, "Our goal is for NXI-101 to enter clinical trials in 2024."

Nexi, established in 2021, has a platform technology to discover factors that cause refractoriness to existing immunotherapy drugs. The company explains that it is a platform technology that discovers the cause of anti-cancer immunotherapy drugs not working well and then develops a drug that targets and eliminates or suppresses the cause.

GC Green Cross, which participated in this investment, plans to seek mid- to long-term cooperation with NexI as a strategic investor (SI).

On October 17, 2022 Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company reported that focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications (Press release, Race Oncology, OCT 17, 2022, View Source [SID1234622381]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zantrene is a highly targeted precision oncology agent as well as a chemotherapy cardioprotective. The drug is the most potent small molecule inhibitor of the key epitransgenomic Fatso/Fat mass and obesity-associated (FTO) protein.

Zantrene’s dual blockbuster potential

The market opportunity for Zantrene is large with the global FTO addressable cancer market estimated to be more than US$120bn in 2020. RAC expects to generate oncology revenues from: (a) FTO-driven cancers including acute myeloid leukaemia (AML), melanoma, renal cancer, breast and pancreatic, and colorectal cancers; and (b) Protection from anthracycline and proteasome inhibitor cardiac damage which is an independent multi-billion dollar opportunity.

Notably, in pre-clinical models Zantrene protects the heart from anthracycline and proteasome inhibitor induced damage while providing improved anti-cancer treatments. We believe this is an unmatched differentiator for the company.

Success in AML is likely to drive growth in near term

RAC has completed a Phase II single agent clinical trial pertaining to the use of Zantrene in treating relapsed/refractory AML and is currently in another two Phase I/II trials exploring combination treatment in AML as well as treatment of extra-medullary AML. Furthermore, it is in the process of preparing to file an Investigational New Drug application in the US (US IND) for extramedullary AML, besides owning an orphan drug designation for the treatment of AML in the US.

We think that success in the AML field will be a springboard for the company to support its other growth pillars, viz., cardioprotection (breast and other cancers), melanoma and renal cancer programmes.

Valuation range of A$6.61-A$11.91 per share

We value RAC at A$3.4bn base case and A$6.1bn bull case. Adjusting for probability and accounting for future capital raises, this equates to A$6.61 per share base case and A$11.91 per share bull case. We have used a DCF approach assuming Zantrene is commercialised according to forecasted timelines. Commercialisation could occur either by RAC or a potential partner that would acquire Zantrene and/or RAC. Key risks to our model include clinical, regulatory, commercial and competition risks.

On October 18, 2022 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany) (Press release, Evotec, OCT 17, 2022, View Source [SID1234622120]). PanHunter is Evotec’s PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years. Evotec now makes PanHunter available to collaborators and partners as a software-as-a-service ("SaaS") product.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PanHunter originates from Evotec’s commitment towards patient-centric, PanOmics-driven drug discovery. The amount of available PanOmics data is growing at exponential rates in the public domain and in the pharmaceutical industry. More PanOmics data has been generated in the last two years than in all previous years combined. These PanOmics data hold an overwhelming amount of information about the condition of the respective patients, the molecular biological context, and causes of diseases. To extract such insights and new knowledge from data, it is paramount to use the smartest and easiest-to-use analytical tools and make them available to all scientists across disciplines.

PanHunter is unique in its ability to integrate the analysis of PanOmics data, designed as an easy-to-use yet fully comprehensive PanOmics data analysis platform. It thereby supports, for instance, the stratification of patient populations via molecular mechanisms and the prediction of efficacy and toxicity profiles of drug candidates given appropriate data inputs. With the launch of the first commercial version of the software at Bio-IT World Europe, Evotec makes PanHunter available to interested partners to accelerate their data-driven research.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "In the ever-accelerating world of Omics driven drug discovery we are excited to release PanHunter. PanHunter is our contribution to enable scientists to handle huge high-dimensional data sets to better understand diseases on a molecular level. Improved molecular understanding of disease as well as drug candidates accelerates the drug discovery process and improves probabilities of success in the pre-clinic and clinic."

Dr Matthias Evers, Chief Business Officer of Evotec, said: "With our first commercial release, we are making a bold claim that the future of successful drug discovery lies in convergence between science and tech. With PanHunter we enable scientists across disciplines to explore this potential and engage in patient-driven, PanOmics-informed drug discovery towards deep disease understanding and achieving tractable insights. It is another step to overcome the limitations of a reductionist R&D approach and use AI to unleash disease understanding and improve success rates ("POS")."

On October 17, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that it will host an update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) on November 14, 2022 (Press release, Sellas Life Sciences, OCT 17, 2022, View Source [SID1234622071]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call will be facilitated by SELLAS management, including SELLAS’ President and CEO, Angelos Stergiou, MD, ScD h.c., and Senior Vice President, Clinical Development, Dragan Cicic, MD, who will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies Research at the Baylor University Medical Center, and member of the REGAL Steering Committee. Further details regarding how to access the update call will be provided in the coming weeks.